PubRank

Simon P L Travis

Author PubWeight™ 47.50‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011 4.79
2 Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012 4.24
3 Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012 3.02
4 Use of endoscopy for management of acute upper gastrointestinal bleeding in the UK: results of a nationwide audit. Gut 2010 2.82
5 IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 2011 2.74
6 The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol 2010 1.74
7 TUCAN (CARD8) genetic variants and inflammatory bowel disease. Gastroenterology 2006 1.73
8 Weight loss at high altitude: pathophysiology and practical implications. Eur J Gastroenterol Hepatol 2006 1.68
9 A common CTLA4 haplotype associated with coeliac disease. Eur J Hum Genet 2005 1.65
10 Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials 2007 1.62
11 Obstructing giant post-inflammatory polyposis in ulcerative colitis: Case report and review of the literature. J Crohns Colitis 2008 1.28
12 A basal gradient of Wnt and stem-cell number influences regional tumour distribution in human and mouse intestinal tracts. Gut 2012 1.16
13 Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol 2011 1.16
14 The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol 2011 1.15
15 The pattern and outcome of acute severe colitis. J Crohns Colitis 2010 1.06
16 Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 2006 1.01
17 The role of CMV in steroid-resistant ulcerative colitis: A systematic review. J Crohns Colitis 2009 1.00
18 Medical management of Crohn's disease. BMJ 2008 0.97
19 Restrictive vs liberal blood transfusion for acute upper gastrointestinal bleeding: rationale and protocol for a cluster randomized feasibility trial. Transfus Med Rev 2013 0.95
20 Prevalence, management, and outcomes of patients with coagulopathy after acute nonvariceal upper gastrointestinal bleeding in the United Kingdom. Transfusion 2012 0.89
21 Biosimilars in IBD: hope or expectation? Gut 2013 0.88
22 Red blood cell transfusion practice in patients presenting with acute upper gastrointestinal bleeding: a survey of 815 UK clinicians. Transfusion 2011 0.86
23 Thiopurine therapy: when to start and when to stop. Eur J Gastroenterol Hepatol 2003 0.86
24 What is the optimal treatment for anemia in inflammatory bowel disease? Curr Drug Deliv 2012 0.85
25 Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2011 0.85
26 The European consensus on ulcerative colitis: new horizons? Gut 2008 0.83
27 Comparison between prospective and retrospective evaluation of Crohn's disease activity index. Am J Gastroenterol 2005 0.82
28 Therapy of ulcerative colitis: state of the art. Curr Opin Gastroenterol 2008 0.79
29 How to manage the infectious risk under anti-TNF in inflammatory bowel disease. Curr Drug Targets 2010 0.79
30 Conventional drug therapy for inflammatory bowel disease. Scand J Gastroenterol 2015 0.78
31 Role of tumor necrosis factor in Crohn's disease. Curr Opin Investig Drugs 2002 0.77
32 Recurrent posterior scleritis and orbital myositis as extra-intestinal manifestations of Crohn's disease: Case report and systematic literature review. J Crohns Colitis 2008 0.77
33 Therapeutic inhibitors of tumor necrosis factor in Crohn's disease. Curr Opin Investig Drugs 2002 0.76
34 An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial. J Crohns Colitis 2008 0.76
35 An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial. J Crohns Colitis 2009 0.76
36 Acute upper gastrointestinal bleeding: identifying low risk patients. Gut 2012 0.75
37 Causality and Chance in the Development of Cancer. N Engl J Med 2015 0.75
38 IBD and IBS: novel mechanisms and future practice. Preface. Dig Dis 2010 0.75
39 Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med 2017 0.75